Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice

Journal of Lipid Research

Volumn 55, Issue 11, 2014, Pages 2389-2400

  Tang, Xiaoyun ^a   Benesch, Matthew G K ^a   Dewald, Jay ^a   Zhao, Yuan Y ^a   Patwardhan, Neeraj ^b   Santos, Webster L ^b   Curtis, Jonathan M ^a   McMullen, Todd P W ^a   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Autotaxin; Breast cancer; Cell migration; Epidermal growth factor receptor; G protein coupled receptors; Lysophosphatidate; Thyroid cancer

Indexed keywords

CALCIUM; GREEN FLUORESCENT PROTEIN; LIPID PHOSPHATE PHOSPHATASE 1; LYSOPHOSPHATIDIC ACID; PHOSPHATASE; RHO KINASE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; LIPID PHOSPHATE PHOSPHATASE; LYSOPHOSPHOLIPID; PHOSPHATIDATE PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER PREVENTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIPID DEGRADATION; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; TUMOR GROWTH; TUMOR VOLUME; WILD TYPE; ANIMAL; CELL MOTION; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; LYSOPHOSPHOLIPIDS; MICE; NEOPLASM METASTASIS; PHOSPHATIDATE PHOSPHATASE; SIGNAL TRANSDUCTION;

EID: 84912018915     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M053462     Document Type: Article

References (38)

1. Boutin, J. A., and G. Ferry. 2009. Autotaxin. Cell. Mol. Life Sci. 66: 3009-3021.
2. Samadi, N., R. Bekele, D. Capatos, G. Venkatraman, M. Sariahmetoglu, and D. N. Brindley. 2011. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. 93: 61-70.
3. Benesch, M. G., Y. M. Ko, T. P. McMullen, and D. N. Brindley. 2014. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 588: 2712-2727.
4. Euer, N., M. Schwirzke, V. Evtimova, H. Burtscher, M. Jarsch, D. Tarin, and U. H. Weidle. 2002. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res. 22: 733-740.
5. Liu, S., M. Umezu-Goto, M. Murph, Y. Lu, W. Liu, F. Zhang, S. Yu, L. C. Stephens, X. Cui, G. Murrow, et al. 2009. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 15: 539-550.
6. Popnikolov, N. K., B. H. Dalwadi, J. D. Thomas, G. J. Johannes, and W. T. Imagawa. 2012. Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma. Tumour Biol. 33: 2237-2243.
7. Samadi, N., C. Gaetano, I. S. Goping, and D. N. Brindley. 2009. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 28: 1028-1039.
8. Samadi, N., R. T. Bekele, I. S. Goping, L. M. Schang, and D. N. Brindley. 2011. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS ONE. 6: e20608.
9. Zhang, R., J. Wang, S. Ma, Z. Huang, and G. Zhang. 2011. Requirement of Osteopontin in migration and the protection against Taxol-induced apoptosis via ATX-LPA axis in SGC7901 cells. BMC Cell Biol. 12: 11.
10. Vidot, S., J. Witham, R. Agarwal, S. Greenhough, H. S. Bamrah, G. J. Tigyi, S. B. Kaye, and A. Richardson. 2010. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell. Signal. 22: 926-935.
11. Bekele, R., and D. N. Brindley. 2012. Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and radiotherapy. Clin. Lipidol. 7: 313-328.
12. Deng, W., E. Shuyu, R. Tsukahara, W. J. Valentine, G. Durgam, V. Gududuru, L. Balazs, V. Manickam, M. Arsura, L. VanMiddlesworth, et al. 2007. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology. 132: 1834-1851.
13. Benesch, M. G., X. Tang, T. Maeda, A. Ohhata, Y. Y. Zhao, B. P. Kok, J. Dewald, M. Hitt, J. M. Curtis, T. P. McMullen, et al. 2014. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28: 2655-2666.
14. Kok, B. P., G. Venkatraman, D. Capatos, and D. N. Brindley. 2012. Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases. Chem. Rev. 112: 5121-5146.
15. Brindley, D. N., and C. Pilquil. 2009. Lipid phosphate phosphatases and signaling. J. Lipid Res. 50 (Suppl.): S225-S230.
16. Sigal, Y. J., M. I. McDermott, and A. J. Morris. 2005. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J. 387: 281-293.
17. Jasinska, R., Q. X. Zhang, C. Pilquil, I. Singh, J. Xu, J. Dewald, D. A. Dillon, L. G. Berthiaume, G. M. Carman, D. W. Waggoner, et al. 1999. Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters. Biochem. J. 340: 677-686.
18. Tomsig, J. L., A. H. Snyder, E. V. Berdyshev, A. Skobeleva, C. Mataya, V. Natarajan, D. N. Brindley, and K. R. Lynch. 2009. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 419: 611-618.
19. Yue, J., K. Yokoyama, L. Balazs, D. L. Baker, D. Smalley, C. Pilquil, D. N. Brindley, and G. Tigyi. 2004. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell. Signal. 16: 385-399.
20. Alderton, F., P. Darroch, B. Sambi, A. McKie, I. S. Ahmed, N. Pyne, and S. Pyne. 2001. G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells. J. Biol. Chem. 276: 13452-13460.
21. Pilquil, C., J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley. 2006. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. J. Biol. Chem. 281: 38418-38429.
22. Ile, K. E., R. Tripathy, V. Goldfinger, and A. D. Renault. 2012. Wunen, a Drosophila lipid phosphate phosphatase, is required for septate junction-mediated barrier function. Development. 139: 2535-2546.
23. Martin, A., A. Gomez-Munoz, D. W. Waggoner, J. C. Stone, and D. N. Brindley. 1993. Decreased activities of phosphatidate phosphohydrolase and phospholipase D in ras and tyrosine kinase (fps) transformed fibroblasts. J. Biol. Chem. 268: 23924-23932.
24. Imai, A., T. Furui, T. Tamaya, and G. B. Mills. 2000. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J. Clin. Endocrinol. Metab. 85: 3370-3375.
25. Tanyi, J. L., Y. Hasegawa, R. Lapushin, A. J. Morris, J. K. Wolf, A. Berchuck, K. Lu, D. I. Smith, K. Kalli, L. C. Hartmann, et al. 2003. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin. Cancer Res. 9: 3534-3545.
26. Boucharaba, A., C. M. Serre, J. Guglielmi, J. C. Bordet, P. Clezardin, and O. Peyruchaud. 2006. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA. 103: 9643-9648.
27. Hooks, S. B., W. L. Santos, D. S. Im, C. E. Heise, T. L. Macdonald, and K. R. Lynch. 2001. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Biol. Chem. 276: 4611-4621.
28. Brindley, D. N., J. Xu, R. Jasinska, and D. W. Waggoner. 2000. Analysis of ceramide 1-phosphate and sphingosine-1-phosphate phosphatase activities. Methods Enzymol. 311: 233-244.
29. Tang, X. J., Y. H. Fu, Q. H. Meng, L. M. Li, X. Y. Ying, M. Han, Q. J. He, B. Yang, S. Zeng, Y. Z. Hu, et al. 2013. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo. Int. J. Pharm. 456: 243-250.
30. Sabri, A., J. Short, J. Guo, and S. F. Steinberg. 2002. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ. Res. 91: 532-539.
31. Tang, X., Z. Sun, C. Runne, J. Madsen, F. Domann, M. Henry, F. Lin, and S. Chen. 2011. A critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer. J. Biol. Chem. 286: 13244-13254.
32. Bahrami, F., D. L. Morris, and M. H. Pourgholami. 2012. Tetracyclines: drugs with huge therapeutic potential. Mini Rev. Med. Chem. 12: 44-52.
33. Smyth, S. S., P. Mueller, F. Yang, J. A. Brandon, and A. J. Morris. 2014. Arguing the case for the autotaxin-lysophosphatidic acidlipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 34: 479-486.
34. Brindley, D. N., F. T. Lin, and G. J. Tigyi. 2013. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta. 1831: 74-85.
35. Zhang, Q. X., C. S. Pilquil, J. Dewald, L. G. Berthiaume, and D. N. Brindley. 2000. Identification of structurally important domains of lipid phosphate phosphatase-1: implications for its sites of action. Biochem. J. 345: 181-184.
36. Pyne, N. J., and S. Pyne. 2010. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer. 10: 489-503.
37. Shida, D., K. Takabe, D. Kapitonov, S. Milstien, and S. Spiegel. 2008. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets. 9: 662-673.
38. Brindley, D. N. 2004. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell. Biochem. 92: 900-912.